Healthcare
Novo Nordisk Bets €1.165 Billion on Longer-Acting Obesity and Diabetes Injections
Novo Nordisk has licensed Nanexa’s PharmaShell platform in a deal worth up to €1.165 billion, targeting monthly or potentially quarterly…
Novo Nordisk has licensed Nanexa’s PharmaShell platform in a deal worth up to €1.165 billion, targeting monthly or potentially quarterly…
Read next